These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2196146)

  • 1. Stimulant drug treatment of hyperactivity: biochemical correlates.
    Elia J; Borcherding BG; Potter WZ; Mefford IN; Rapoport JL; Keysor CS
    Clin Pharmacol Ther; 1990 Jul; 48(1):57-66. PubMed ID: 2196146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of methylphenidate on urinary catecholamine excretion in hyperactivity: a partial replication.
    Zametkin AJ; Hamburger SD
    Biol Psychiatry; 1988 Feb; 23(4):350-6. PubMed ID: 3342265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine.
    Zametkin AJ; Karoum F; Linnoila M; Rapoport JL; Brown GL; Chuang LW; Wyatt RJ
    Arch Gen Psychiatry; 1985 Mar; 42(3):251-5. PubMed ID: 2579615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment.
    Zametkin A; Rapoport JL; Murphy DL; Linnoila M; Karoum F; Potter WZ; Ismond D
    Arch Gen Psychiatry; 1985 Oct; 42(10):969-73. PubMed ID: 2412521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings.
    Donnelly M; Rapoport JL; Potter WZ; Oliver J; Keysor CS; Murphy DL
    Arch Gen Psychiatry; 1989 Mar; 46(3):205-12. PubMed ID: 2645848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary excretion of catecholamines and their metabolites in relation to circulating catecholamines. Six-hour infusion of epinephrine and norepinephrine in healthy volunteers.
    Moleman P; Tulen JH; Blankestijn PJ; Man in 't Veld AJ; Boomsma F
    Arch Gen Psychiatry; 1992 Jul; 49(7):568-72. PubMed ID: 1627048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Day-to-day intraindividual reliability and interindividual differences in monoamines excretion.
    Curtin F; Walker JP; Schulz P
    J Affect Disord; 1996 Jun; 38(2-3):173-8. PubMed ID: 8791186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary catecholamine metabolites in hyperkinetic boys treated with d-amphetamine.
    Shekim WO; Dekirmenjian H; Chapel JL
    Am J Psychiatry; 1977 Nov; 134(11):1276-9. PubMed ID: 910984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?
    Elia J; Borcherding BG; Rapoport JL; Keysor CS
    Psychiatry Res; 1991 Feb; 36(2):141-55. PubMed ID: 2017529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder.
    Castellanos FX; Elia J; Kruesi MJ; Gulotta CS; Mefford IN; Potter WZ; Ritchie GF; Rapoport JL
    Psychiatry Res; 1994 Jun; 52(3):305-16. PubMed ID: 7527565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder.
    Castellanos FX; Elia J; Kruesi MJ; Marsh WL; Gulotta CS; Potter WZ; Ritchie GF; Hamburger SD; Rapoport JL
    Neuropsychopharmacology; 1996 Feb; 14(2):125-37. PubMed ID: 8822535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
    Pelham WE; Greenslade KE; Vodde-Hamilton M; Murphy DA; Greenstein JJ; Gnagy EM; Guthrie KJ; Hoover MD; Dahl RE
    Pediatrics; 1990 Aug; 86(2):226-37. PubMed ID: 2196522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis.
    Arnold LE; Christopher J; Huestis R; Smeltzer DJ
    Arch Gen Psychiatry; 1978 Apr; 35(4):463-73. PubMed ID: 365123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
    Ramtvedt BE; Aabech HS; Sundet K
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):130-9. PubMed ID: 24666268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of d-amphetamine on urinary metabolites of dopamine and norepinephrine in hyperactive boys.
    Shekim WO; Javaid J; Dekirmenjian H; Chapel JL; Davis JM
    Am J Psychiatry; 1982 Apr; 139(4):485-8. PubMed ID: 7065295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in urinary excretion of catecholamines and their metabolites in pediatric dental patients.
    Sakuma N; Nagasaka N
    ASDC J Dent Child; 1996; 63(2):118-22. PubMed ID: 8708120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary MHPG and HVA excretion in boys with attention deficit disorder and hyperactivity treated with d-amphetamine.
    Shekim WO; Javaid J; Davis JM; Bylund DB
    Biol Psychiatry; 1983 Jun; 18(6):707-14. PubMed ID: 6871304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary monoamine metabolites in children with minimal brain dysfunction.
    Wender PH; Epstein RS; Kopin IJ; Gordon EK
    Am J Psychiatry; 1971 Apr; 127(10):1411-5. PubMed ID: 5549938
    [No Abstract]   [Full Text] [Related]  

  • 19. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
    Akhondzadeh S; Mohammadi MR; Khademi M
    BMC Psychiatry; 2004 Apr; 4():9. PubMed ID: 15070418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary catecholamines in attention-deficit hyperactivity disorder with and without comorbid anxiety.
    Pliszka SR; Maas JW; Javors MA; Rogeness GA; Baker J
    J Am Acad Child Adolesc Psychiatry; 1994 Oct; 33(8):1165-73. PubMed ID: 7982867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.